Skip to main content
[Replay] Videoconference – H1 2024-25 Results
December 10, 2024
Consolidated Half-Year Financial Results
December 10, 2024
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
December 9, 2024
Videoconference and publication of half-year financial results, Tuesday, December 10, 2024
November 29, 2024
25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
November 6, 2024
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
November 4, 2024
Participation in Leading Investor Conferences
October 28, 2024
New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI
September 23, 2024
New Treatment Insights into Switching to UZEDY® from Perseris®
September 23, 2024
Reporting of the 2024 Annual General Meeting
September 13, 2024
